Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PBP1510 (ulenistamab) targets pancreatic adenocarcinoma upregulated factor, a tumour-specific protein, found to be overexpressed in majority of pancreatic cancer cases. It represents a promising therapeutic strategy for addressing the unmet medical needs of pancreatic cancer patients.
Lead Product(s): Ulenistamab,Gemcitabine
Therapeutic Area: Oncology Product Name: PBP1510
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Tuznue (trastuzumab) targets HER2, which is overexpressed in some types of cancer cells and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Product Name: Tuznue
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
Prestige´s bevacizumab (HD204) is a mAb biosimilar to Roche’s Avastin®, an inhibitor of vascular endothelial growth factor (VEGF), which is used in combination with other therapies to treat patients with multiple forms of cancer.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: HD20
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Intas Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 26, 2022
Details:
PBP1510 (ulenistamab), a first-in-class anti-PAUF monoclonal antibody,is envisioned to provide significant benefit to all patients affected by PAUF-positive pancreatic cancer.
Lead Product(s): PBP1510,Gemcitabine
Therapeutic Area: Oncology Product Name: PBP1510
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
Through MOU, Prestige and Vaxine will be building a partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine, Covax-19® and then as Covid-19 enters an endemic phase development of a next generation Covid19/influenza combo vaccine.
Lead Product(s): Covax-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikogen
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Vaxine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2022
Details:
The study met its primary endpoint (tpCR) and showed equivalent efficacy and comparable safety profile for Troika (HD201), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2 positive breast and metastatic gastric cancer.
Lead Product(s): Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Troika
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Details:
Preclinical data of PBP1510 presented in the poster shows notable regression in tumour volume and weight in subcutaneous as well as orthotopic patient derived cancer xenograft (PDX) mouse models treated with PBP1510 compared to gemcitabine and IgG controls.
Lead Product(s): PBP1510,Gemcitabine
Therapeutic Area: Oncology Product Name: PBP1510
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Under this partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy’s will be responsible for local registrations, marketing and sales in the licensed territories.
Lead Product(s): Trastuzumab,Docetaxel
Therapeutic Area: Oncology Product Name: HD201
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 09, 2021
Details:
French National Agency for the Safety of Medicines and Health Products (L'Agence nationale de sécurité du medicament, ANSM) has approved a phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.
Lead Product(s): PBP1510
Therapeutic Area: Oncology Product Name: PBP1510
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
French National Agency for the Safety of Medicines and Health Products has approved a Phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.
Lead Product(s): PBP1510
Therapeutic Area: Oncology Product Name: PBP1510
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2021